Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	9.67B
Revenue (ttm)	6.20B
Net Income (ttm)	290.70M
Shares Out	11.78M
EPS (ttm)	32.61
PE Ratio	25.17
Forward PE	n/a
Dividend	0.75 (0.09%)
Ex-Dividend Date	Sep 18, 2025

Volume	3,400
Average Volume	4,135
Open	840.00
Previous Close	841.50
Day's Range	820.00 - 850.00
52-Week Range	819.00 - 1,416.45
Beta	0.65
RSI	34.13
Earnings Date	Aug 8, 2025

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical consultancy services to various distributors and contract manufacturing services. The company offers capsule, cream, eye drop, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, ...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 48
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.44% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 34.98%.